John Haurum (F-Star Biotechnology Ltd. (F-Star Therapeutics))

Haurum, John (F-Star 201205–201810 CEO before ImClone System + Symphogen LEFT 10/18)

	Organisation	F-Star Biotechnology Ltd. (F-Star Therapeutics)
	Group	Sino Biopharm (Group)
	Former/major organisation	ImClone Systems Inc.
	Group	Eli Lilly (Group)
	Product	mAb2 bispecific antibody platform

Record changed: 2024-11-26

Picture Berlin Partner Top News Robotics Network Berlin-Brandenburg 650x200px

More documents for John Haurum

[1] Synklino ApS. (6/8/22). "Press Release: Synklino Completes Series A Raise of EUR 29.8 Million to Advance Clinical Trials of Its Drug Candidate for the Treatment of Cytomegalovirus (CMV)". Copenhagen....
[2] Synklino ApS. (11/15/21). "Press Release: Financing Round in Synklino Heavily Oversubscribed". Copenhagen....
[3] Adcendo ApS. (7/6/21). "Press Release: Adcendo Appoints Michael Pehl as Chief Executive Officer"....
[4] Catalym GmbH. (5/4/21). "Press Release: Catalym Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer". Munich....
[5] Adcendo ApS. (4/29/21). "Press Release: Adcendo Raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers". Copenhagen....
[6] Storm Therapeutics Ltd.. (6/27/19). "Press Release: Storm Therapeutics Appoints Dr John Haurum to the Board of Directors". Cambridge....
[7] Agomab Therapeutics N.V.. (4/3/19). "Press Release: AgomAb Therapeutics Completes Euros 21m Series A Financing". Ghent....
[8] NeoPhore Ltd.. (3/20/19). "Press Release: NeoPhore Appoints Dr John Haurum as Non-Executive Director. Former F-star CEO Joins the Board of Directors"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]